NCT04600362: DUPINUM

Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema

Active, enrolled Phase 2 Last updated 23 September 2025

What this trial tests

Phase 2 trial testing Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] in Nummular Eczema in 70 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

30 March 2021

Primary endpoint
1 September 2025

31 January 2027

Quick facts

Lead sponsor	Technical University of Munich
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	70
Start date	30 March 2021
Primary completion	1 September 2025
Estimated completion	31 January 2027
Sites	1 location across Germany

Drugs / interventions tested

• Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT] — full drug profile →

Conditions studied

• Nummular Eczema — all drugs for Nummular Eczema →

Sponsor

Technical University of Munich

Who can join

Adults 18 to 85, any sex, with Nummular Eczema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nummular eczema (NE) is an idiopathic chronic inflammatory skin disease that occurs throughout all life periods. Diagnosis is made primarily clinically in correlation with histological findings. Treatment of NE is difficult. Standard treatment consists of the use of emollients, topical as well as systemic corticosteroids and phototherapy. Nevertheless, remission is hard to achieve and relapse occurs often. Patients usually suffer from severe pruritus and reduced quality of life. Therefore, new therapeutic strategies are urgently needed.

Dupilumab (Dupixent®), a monoclonal antibody inhibiting the IL-4 and IL-13 pathway by targeting the IL-4-receptor, has been approved for the treatment of moderate-to-severe atopic dermatitis (AD). Since there is an overlap between AD and NE with both being caused by impaired epidermal barrier, broad immune-mediated inflammation and microbial skin colonization, using Dupilumab in NE seems to be promising.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

1. Dupilumab in Inflammatory Skin Diseases: A Systematic Review.
   Olbrich H, Sadik CD, Ludwig RJ, Thaçi D, et al · · 2023 · cited 67× · PMID 37189381 · DOI 10.3390/biom13040634
2. Clinical Measurement of Transepidermal Water Loss.
   Kundu D, Jayaraman A, Sen CK. · · 2026 · cited 4× · PMID 40476522 · DOI 10.1089/wound.2024.0148
3. A phase IIb single-center study to assess the efficacy of apremilast for the treatment of nummular eczema.
   Böhner A, Seiringer P, Kleeberger V, Rogner D, et al · · 2025 · cited 1× · PMID 40548467 · DOI 10.1111/ddg.15786
4. Monozentrische Phase‐IIb‐Studie zur Wirksamkeit von Apremilast beim nummulärem Ekzem
   Böhner A, Seiringer P, Lang V, Rogner D, et al · · 2025